Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die Wachstumsgeschichte: Analysten sehen kurzfristige +37 %-Chance bei diesem europäischen Marktführer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Übersicht Suchergebnisse zum Thema POXEL

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
DoPoxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update237TWYMEEG gross sales in Japan for Sumitomo Pharma Fiscal Year 20231 reached JPY 4.6 billion (EUR 27.9 million)2, exceeding guidance3 by more than 8% TWYMEEG's FY 2024 forecast4 of JPY 11.3...
► Artikel lesen
29.04.Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release273TWYMEEG gross sales in Japan should exceed its FY 20231 guidance2 of JPY 4.2 billion (EUR 25.7 million)3 driven by a favourable sales trend in Japan. Sumitomo Pharma to report full year results...
► Artikel lesen
28.03.Poxel to Report Its 2023 Annual Results by the End of April 2024330Exclusive discussions and finalization of related documentation underway with a leading investor to monetize royalties from TWYMEEG (Imeglimin) sales in Japan Cash runway estimated to be...
► Artikel lesen
15.02.Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update377TWYMEEG sales continue to perform well in Japan with JPY 3.5 billion (EUR 22.4 million1) total sales over the first 3 quarters of 20232, up +170% vs. the corresponding period in 2022. This growth...
► Artikel lesen
03.01.Poxel Announces its Financial Calendar for 2024396Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
21.12.23Poxel Provides Corporate Update492The Company remains focused on securing additional financing to execute its strategic plan in rare diseases Exclusive discussions with a leading investor to monetize royalties from TWYMEEG...
► Artikel lesen